Efficacy and safety of siponimod in secondary progressive multiple sclerosis-Results of the placebo controlled, double-blind, Phase III EXPAND study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2016
This article has no abstract
Epistemonikos ID: 47ddd48aab8af85daa73ea738f279cdda9237c33
First added on: Apr 29, 2026